46 related articles for article (PubMed ID: 30826877)
1. What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?
Kumarasinghe MP; Houghton D; Allanson BM; Price TJ
Surg Pathol Clin; 2023 Dec; 16(4):659-672. PubMed ID: 37863558
[TBL] [Abstract][Full Text] [Related]
2. Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome.
Puhr HC; Pablik E; Berghoff AS; Jomrich G; Schoppmann SF; Preusser M; Ilhan-Mutlu A
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32188713
[TBL] [Abstract][Full Text] [Related]
3. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY; Kawazoe A; Yañez P; Li N; Lonardi S; Kolesnik O; Barajas O; Bai Y; Shen L; Tang Y; Wyrwicz LS; Xu J; Shitara K; Qin S; Van Cutsem E; Tabernero J; Li L; Shah S; Bhagia P; Chung HC
Nature; 2021 Dec; 600(7890):727-730. PubMed ID: 34912120
[TBL] [Abstract][Full Text] [Related]
4. Deep learning model based on multi-lesion and time series CT images for predicting the benefits from anti-HER2 targeted therapy in stage IV gastric cancer.
He M; Chen ZF; Liu S; Chen Y; Zhang H; Zhang L; Zhao J; Yang J; Zhang XT; Shen L; Gao JB; Dong B; Tang L
Insights Imaging; 2024 Feb; 15(1):59. PubMed ID: 38411839
[TBL] [Abstract][Full Text] [Related]
5. Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target.
Rogers JE; Yamashita K; Sewastjanow-Silva M; Trail A; Waters RE; Ajani J
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958354
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).
Tintelnot J; Stein A; Al-Batran SE; Ettrich T; Götze T; Grün B; Haag GM; Heuer V; Hofheinz RD; Homann N; Bröring TS; Cruz MS; Kurreck A; Lorenzen S; Moosmann N; Müller C; Schuler M; Siegler G; Binder M; Gökkurt E
Front Oncol; 2023; 13():1272175. PubMed ID: 37909020
[TBL] [Abstract][Full Text] [Related]
7. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade.
He M; Chen ZF; Zhang L; Gao X; Chong X; Li HS; Shen L; Ji J; Zhang X; Dong B; Li ZY; Lei T
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349127
[TBL] [Abstract][Full Text] [Related]
8. HER2 expression in urothelial carcinoma, a systematic literature review.
Scherrer E; Kang A; Bloudek LM; Koshkin VS
Front Oncol; 2022; 12():1011885. PubMed ID: 36338710
[TBL] [Abstract][Full Text] [Related]
9. Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study.
Kolbe K; Haffner I; Schierle K; Maier D; Geier B; Luber B; Bläker H; Wittekind C; Lordick F
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1319-1329. PubMed ID: 36030286
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of multivariate models integrating preoperative clinicopathological and radiographic findings to predict HER2 status in gastric cancer.
Xu M; Liu S; Li L; Qiao X; Ji C; Tan L; Zhou Z
Sci Rep; 2022 Aug; 12(1):14177. PubMed ID: 35986169
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer.
Díaz Del Arco C; Estrada Muñoz L; Ortega Medina L; Molina Roldán E; Cerón Nieto MÁ; García Gómez de Las Heras S; Fernández Aceñero MJ
World J Gastrointest Oncol; 2022 Jun; 14(6):1162-1174. PubMed ID: 35949214
[TBL] [Abstract][Full Text] [Related]
12. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
Haffner I; Schierle K; Raimúndez E; Geier B; Maier D; Hasenauer J; Luber B; Walch A; Kolbe K; Riera Knorrenschild J; Kretzschmar A; Rau B; Fischer von Weikersthal L; Ahlborn M; Siegler G; Fuxius S; Decker T; Wittekind C; Lordick F
J Clin Oncol; 2021 May; 39(13):1468-1478. PubMed ID: 33764808
[TBL] [Abstract][Full Text] [Related]
13. Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.
Díaz Del Arco C; Ortega Medina L; Estrada Muñoz L; García Gómez de Las Heras S; Fernández Aceñero MJ
Histol Histopathol; 2021 Jun; 36(6):587-613. PubMed ID: 33565601
[TBL] [Abstract][Full Text] [Related]
14. Impact of chromosome 17 centromere copy number increase on patient survival and human epidermal growth factor receptor 2 expression in gastric adenocarcinoma.
Ciesielski M; Szajewski M; Walczak J; Pęksa R; Lenckowski R; Supeł M; Zieliński J; Kruszewski WJ
Oncol Lett; 2021 Feb; 21(2):142. PubMed ID: 33552261
[TBL] [Abstract][Full Text] [Related]
15. HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.
Baretton G; Kreipe HH; Schirmacher P; Gaiser T; Hofheinz R; Berghäuser KH; Koch W; Künzel C; Morris S; Rüschoff J;
Virchows Arch; 2019 May; 474(5):551-560. PubMed ID: 30826877
[TBL] [Abstract][Full Text] [Related]
16. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.
Rüschoff J; Lebeau A; Kreipe H; Sinn P; Gerharz CD; Koch W; Morris S; Ammann J; Untch M;
Mod Pathol; 2017 Feb; 30(2):217-226. PubMed ID: 27767099
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
18. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
